Amount Raised
$50 Million
Round Type
series b
Description
LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investors. The financing was led by Rick Klausner and Milky Way Investments, with participation from existing investors GV (formerly Google Ventures), WuXi Healthcare Ventures, Foresite Capital, Arch Ventures, Blue Pool Capital, and MRL Ventures Fund. Proceeds from the Series B financing will allow the Company to accelerate and expand its drug discovery efforts, as well as strategically advance select pipeline programs toward clinical development.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech